CANDO and the infinite drug discovery frontier.
CANDO and the infinite drug discovery frontier.
复制标题
DOI:
10.1016/j.drudis.2014.06.018
复制
发表时间:
2014-09
影响因子:
7.4
通讯作者:
Samudrala, Ram
中科院分区:
文献类型:
--
作者:
Minie, Mark;Chopra, Gaurav;Sethi, Geetika;Horst, Jeremy;White, George;Roy, Ambrish;Hatti, Kaushik;Samudrala, Ram
The Computational Analysis of Novel Drug Opportunities (CANDO) platform (http://protinfo.org/cando) uses similarity of compound–proteome interaction signatures to infer homology of compound/drug behavior. We constructed interaction signatures for 3733 human ingestible compounds covering 48,278 protein structures mapping to 2030 indications based on basic science methodologies to predict and analyze protein structure, function, and interactions developed by us and others. Our signature comparison and ranking approach yielded benchmarking accuracies of 12–25% for 1439 indications with at least two approved compounds. We prospectively validated 49/82 ‘high value’ predictions from nine studies covering seven indications, with comparable or better activity to existing drugs, which serve as novel repurposed therapeutics. Our approach may be generalized to compounds beyond those approved by the FDA, and can also consider mutations in protein structures to enable personalization. Our platform provides a holistic multiscale modeling framework of complex atomic, molecular, and physiological systems with broader applications in medicine and engineering.
登录
查看更多内容
影响因子:
2.7
作者:
Jenwitheesuk E;Samudrala R
通讯作者:
Samudrala R
影响因子:
7.4
作者:
Ghaemmaghami, Amir M.;Hancock, Matthew J.;Harrington, Helen;Kaji, Hirokazu;Khademhosseini, Ali
通讯作者:
Khademhosseini, Ali
影响因子:
11.9
作者:
Hur M;Campbell AA;Almeida-de-Macedo M;Li L;Ransom N;Jose A;Crispin M;Nikolau BJ;Wurtele ES
通讯作者:
Wurtele ES
影响因子:
3
作者:
Horst OV;Horst JA;Samudrala R;Dale BA
通讯作者:
Dale BA
影响因子:
14.9
作者:
Fernández-Suárez XM;Galperin MY
通讯作者:
Galperin MY